$17.04
-0.41-2.35%
Últ. Act.: Nov 11, 4:00 PM
Aktis Oncology fell 23.9% from $22.40 to $17.04, behind the S&P 500's +9.5%. Its worst day was Jul 6 (−16.4%), and its low came Nov 2 at $14.59.
Jan 9, 2026 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Aktis Oncology shares fell 13.8%, while the S&P 500 fell 1.7%.
−13.8% · S&P 500 −1.7%
EPS of $-0.38 missed the $-0.33 estimate on $3.2M revenue (est. $2.1M).
+8.0% · S&P 500 −0.2%
Story events cover the past 12 months · Times ET
Aktis Oncology shares rose 12.7%, while the S&P 500 rose 0.5%.
+12.7%, the year's best day · S&P 500 +0.5%
Aktis Oncology closed at its highest level of the year, 43.9% above where the year started.
+7.0% · S&P 500 +0.8%
EPS of $-0.44 missed the $-0.43 estimate on $3.4M revenue (est. $2.5M).
+4.8% · S&P 500 −0.2%
Aktis Oncology shares fell 10.8%, while the S&P 500 fell 0.7%.
−10.8% · S&P 500 −0.7%
Aktis Oncology closed at its lowest level of the year, 34.9% below where the year started.
−8.4% · S&P 500 −0.5%
Where it ended: a close of $17.04 on Nov 11, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.46, revenue est. $2.5M).
Nothing in the past 12 months.
All AKTS dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for AKTS and SPY from Benzinga historical bars. Not investment advice.